2973 results found
Improved flexibility for all Investigator Grant holders
Outcomes of Clinical Trials and Cohort Studies funding rounds.
We recognise that uncertainty about the trajectory and ongoing impacts of the COVID-19 pandemic continues to affect many in Australia’s health and medical research community.
NHMRC promotes the highest quality in the research that it funds.
In addition to the Australian code for the care and use of animals for scientific purposes (the Code), we provide information to help people ensure that the use of animals is ethical, humane, complies with all relevant legislation and the Code, and meets the highest possible standards.
Ensuring the highest quality and value of NHMRC-funded research is a priority for NHMRC. NHMRC’s Research Quality Strategy outlines the key areas NHMRC will focus on to provide guidance and support for good research practices throughout the research cycle.
NHMRC opened the Targeted Call for Research (TCR): Oral Health Care in Australia 2024 on 20 November 2024. Applications closed on 12 February 2025.
The Targeted Call for Research (TCR): Oral Health Care in Australia 2024 aimed to support research into better understanding the apparent gap in the translation and implementation of effective population-level oral health (including health services) interventions. Oral health needs to be considered as an integral part of general health and embedded in the primary care setting. The design and implementation of interventions and policy changes based on this research would reduce overall health system demands and costs in the long-term.
In the 2000s, rising annual Human Immunodeficiency Virus (HIV) diagnoses in Australia highlighted the need for developing new ways of preventing HIV transmission. Researchers at the University of New South Wales’ (UNSW) Kirby Institute and the Centre for Social Research in Health conducted a series of NHMRC-supported studies demonstrating the effectiveness of antiretroviral medicines in preventing transmission. Their work guided the successful scale up of HIV treatment as prevention and pre-exposure prophylaxis (PrEP), resulting in substantial declines in HIV infections in Australia and ensuring Australia remains a global leader in HIV prevention.